Business Combination (Details) - USD ($)		1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 10, 2022	Oct. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Aug. 03, 2022	Jul. 29, 2022	Jul. 11, 2022	Oct. 15, 2018
Business Combination
Common stock, shares issued			17,868,282	15,844,061	17,868,282	15,844,061		2,459,016
Common stock, price per share			$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001		$ 0.001	$ 1,000
Fair value adjustment decrease to contingent consideration					$ (660,000)	$ 2,091,000
V C N
Business Combination
Common stock, shares issued	2,639,530
Amount to be paid due to approval				$ 3,000,000.0
Payment made after clinical trial		$ 3,250,000
Finance costs	$ 417,000
Fair value of contingent consideration	11,093,000		$ 6,300,000	$ 10,200,000	$ 6,300,000	$ 10,200,000
Purchase consideration	22,809,000
V C N | General and administrative expenses
Business Combination
Fair value of contingent consideration	27,800,000
V C N | Grifols Innovation
Business Combination
Consideration purchase paid	$ 4,700,000
Common stock, price per share	$ 0.001
Existing liabilities	$ 2,390,000
Cash payments	$ 70,200,000
Payment made after clinical trial			$ 3,250,000
V C N | New technologies
Business Combination
Business acquisition, percentage of voting interests acquired	86.00%